We highlight an additional layer of complexity accompanying the ΔF508 CFTR mutation and bring attention to the potential significance of ΔF508 CFTR correctors that stabilize band B CFTR as possible components of combination therapeutics for CF. This evidence concerns the gene CFTR and cystic fibrosis.